Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026)
Nuvalent (NUVL) posted Amortizatization of Intangibles of $1.8 million for Q1 2026, down 90.98% on a QoQ basis from $20.3 million in Q4 2025, and down 57.27% year-over-year from $4.3 million in Q1 2025.
Nuvalent (NUVL) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Nuvalent's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 57.27% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (down 61.25% YoY) and the FY2025 annual result came in at $11.1 million, down 24.28% from the prior year.
- Amortizatization of Intangibles was $1.8 million for Q1 2026 at Nuvalent, down from $20.3 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $24.4 million in Q4 2024 and bottomed at -$11.3 million in Q2 2025.
- A 5-year average of $2.2 million and a median of -$833000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Peak annual rise in Amortizatization of Intangibles reached 2275.99% in 2023, while the deepest fall reached 87566.67% in 2023.
- Nuvalent's Amortizatization of Intangibles stood at -$833000.0 in 2022, then jumped by 2275.99% to $18.1 million in 2023, then jumped by 34.64% to $24.4 million in 2024, then slipped by 16.89% to $20.3 million in 2025, then slumped by 90.98% to $1.8 million in 2026.
- Business Quant data shows NUVL's Amortizatization of Intangibles at $1.8 million in Q1 2026, $20.3 million in Q4 2025, and -$2.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Dec 31, 2025 | 20.28 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Sep 30, 2025 | -2.19 Mn |
| Jun 30, 2025 | -11.27 Mn |
| Jun 30, 2025 | -11.27 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 24.41 Mn |
| Dec 31, 2024 | 24.41 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Jun 30, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.38 Mn |
| Mar 31, 2024 | -3.38 Mn |
| Dec 31, 2023 | 18.13 Mn |
| Dec 31, 2023 | 18.13 Mn |